Deal Team

Corporate
Antitrust
Executive Compensation and Benefits
Litigation
Real Estate M&A
Restructuring and Finance
Intellectual Property
Tax

Teva in the proposed divesture of its active-pharmaceutical ingredient (API) business

On January 31, 2024, Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or “TAPI”. TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide.

Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Teva.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.